Effects of Emicizumab Treatment in Patients With Hemophilia A

NCT07190118 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-09-24

No results posted yet for this study

Summary

The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.

Conditions

  • Hemophilia A
  • Musculoskeletal Assessment
  • Musculoskeletal Abnormalities

Sponsors & Collaborators

  • Hasan Kalyoncu University

    lead OTHER

Principal Investigators

  • Tuğba GÖNEN, Asisst. Prof. Dr. · Hasan Kalyoncu University

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2025-11-10
Completion
2026-02-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07190118 on ClinicalTrials.gov